Sponsored by the Academy for Continued Healthcare Learning (ACHL) and the Indiana University School of Medicine (IUSM).
This activity is supported by an educational grant from Janssen Scientific Affairs.
Despite the use of secondary prevention strategies, a percentage of cardiovascular patients still have recurrent events. To address the needs of this patient population, expert faculty Marc Bonaca, MD, MPH, and Christian Ruff, MD review a patient case who appears to be clinically stable, but who is at high risk of MACE. The faculty discuss their clinical outcomes and consider strategies for vascular protection and prevention of events in light of recent data and trial results on combination regimens involving anticoagulants and antiplatelet therapy.
This activity is intended for cardiologists and other healthcare providers who care for patients with atherosclerotic disease.
Upon completion of this activity, participants will be able to:
Discuss long-term atherothrombotic risks in patients with stable cardiovascular disease, including coronary artery disease and peripheral arterial disease
Interpret data from recent clinical trials using antithrombotic therapy for vascular protection
Formulate comprehensive pharmacological regimens for complex, diverse patient populations
Conflict Of Interest Disclosure Policy
Guidelines require that participants in CME/CE activities be made aware of all financial relationships that may be perceived as affecting the presentation of the faculty member. Indiana University School of Medicine (IUSM) ensures that all faculty and staff involved in the planning, development, and implementation of IUSM activities disclose relevant financial relationships and that conflicts of interest are resolved before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.
Marc Bonaca, MD, MPH Director of Vascular Research University of Colorado Executive Director, CPC University of Colorado Hospital Aurora, CO
Dr. Bonaca discloses the following: Consultant: Amgen, Aralez, AstraZeneca, Bayer, Janssen Scientific, and Merck Grant/Research Support: AstraZeneca, Bayer, Merck, and MedImmune
Christian T. Ruff, MD, MPH Assistant Professor of Medicine Harvard Medical School Investigator, TIMI Study Group Cardiovascular Division Brigham and Women’s Hospital Boston, MA
Dr. Ruff discloses the following: Consultant: Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Portola Grant/Research Support: Daiichi Sankyo
ACHL and IUSM staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Indiana University School of Medicine designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. IUSM requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.